Progress in the Curative Treatment of Childhood Hematologic Malignancies
Authors:
- Alan S. WayneAWAlan S. Wayne
- Gregory H. ReamanGRGregory H. Reaman
- Lee J. HelmanLHLee J. Helman
Open Access
- 17 September 2008
- journal article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 100 (18) , 1271-1273
Abstract
Hematologic malignancies account for approximately 40% of childhood cancer ( 1 ). Progress in the curative treatment of this group of cancers is one of the great medical success stories of the 20th century. There have been improvements in outcome for all major subtypes of pediatric leukemias and lymphomas, the most dramatic of which has been in acute lymphoblastic leukemia (ALL), the commonest childhood malignancy. At the time that the National Cancer Act of 1971 (Public Law 92-218) made the “conquest of cancer a national crusade” (President Richard M. Nixon, December 23, 1971) fewer than 10% of children with ALL survived for 10 years after diagnosis. Survival rates for children diagnosed with ALL have increased steadily over ensuing eras and now exceed 80% ( 2 , 3 ). Improvements in survival for childhood hematologic malignancies have been achieved as the result of serial clinical trials conducted by pediatric oncology cooperative groups and large single clinical research centers. Essential to these therapeutic advances has been the development of effective agents, along with combination chemotherapy and treatment phase–specific and central nervous system–directed regimens. The definition of clinical, pathological, and biologic risk groups has facilitated the critically important evolution of risk-based treatment stratification. This risk-based treatment approach occurred largely in the absence of new therapeutic agents over the past decade and represents the application of individualized cancer therapy before the introduction of molecularly targeted agents. Intensified regimens, including the judicious use of stem cell transplantation, have led to better outcomes for higher risk groups and for those who relapse. Equally essential has been the incorporation of aggressive multisystem supportive care, such as transfusion therapy and anti-infectious prophylaxis and treatment. As a consequence, hematologic malignancies, and pediatric oncology clinical trials in general, have become models for the successes of comprehensive cancer care.Keywords
This publication has 7 references indexed in Scilit:
- Trends in 5- and 10-year Survival After Diagnosis with Childhood Hematologic Malignancies in the United States, 1990–2004JNCI: Journal of the National Cancer Institute, 2008
- Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemiaHaematologica, 2007
- Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children’s Oncology Group (COG) Study AALL0031.Blood, 2007
- Chronic Health Conditions in Adult Survivors of Childhood CancerNew England Journal of Medicine, 2006
- Outcome of Childhood Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid and ChemotherapyJournal of Clinical Oncology, 2004
- Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1998
- Fifty Years of Studies of the Biology and Therapy of Childhood LeukemiaBlood, 1997